Disease/Infection News

RSS

Researchers solve the mystery of silent hypoxia caused by COVID-19

More than six months since COVID-19 began spreading in the United States, scientists are still solving the many puzzling aspects of how the novel coronavirus attacks the lungs and other parts of the body.

19 Nov 2020

Study investigates link between myocarditis and COVID-19

As the COVID-19 pandemic evolves, so too does research into its effects on heart health. One particular area of interest for physicians involves whether COVID-19 leads to inflammation of the heart muscle, a condition known as myocarditis.

19 Nov 2020

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

19 Nov 2020

Texas Heart Institute to participate in a study to treat ARDS in hospitalized COVID-19 patients

Texas Heart Institute has been selected as one of up to 60 sites in the world to participate in an international investigative study seeking to aid COVID-19 patients who develop acute respiratory distress syndrome (ARDS).

19 Nov 2020

Antibody combinations may be more effective at preventing, treating COVID-19

Pairs of antibodies may be more effective than single antibodies at preventing and treating COVID-19, according to a new study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University in New York.

19 Nov 2020

Afro-Caribbean patients with end stage kidney disease more likely to be hospitalized with COVID-19

Afro-Caribbean people with end stage kidney disease (ESKD) are more likely to be hospitalized with COVID-19 than other ethnicities, a study has found.

19 Nov 2020

Mosaic RBD nanoparticles elicit neutralizing antibodies against SARS-CoV-2

The researchers show that the mice immunized with homotypic or mosaic nanoparticles produced broad binding and neutralizing responses, in contrast to plasma antibodies elicited in humans by SARS-CoV-2 infection. The RBD nanoparticles induced cross-reactive IgG responses in the immunized mice.

19 Nov 2020

Texas Biomed awarded $1 million to evaluate MAb therapeutics for COVID-19

Texas Biomedical Research Institute in San Antonio, Texas, was awarded $1 million from the Bill & Melinda Gates Foundation to test the efficacy of human monoclonal antibodies (MAbs) for the treatment of SARS-CoV-2 infection.

19 Nov 2020

Swiss data shows COVID-19 three times more deadly than the flu

Despite this, COVID-19 is often downplayed to be only a seasonal flu by many. This may be because both influenza and COVID-19 have a similar initial presentation, and it is tough to distinguish between the two based on just the clinical presentation.

19 Nov 2020

Cannabis use disorder may increase risk of COVID-19 hospitalization

Researchers in the United States have conducted a study suggesting that genetic vulnerability to a psychiatric syndrome called cannabis use disorder (CUD) may increase the risk of developing severe coronavirus disease 2019 (COVID-19) that requires hospitalization.

19 Nov 2020

New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine

Researchers from the United States and The Netherlands have conducted a pre-clinical study supporting the initiation of a Phase 3 trial to test a two-dose regimen of the Janssen Ad26.COV2.S vaccine candidate among adult and elderly individuals.

19 Nov 2020

Study warns elderly individuals less able to reduce contacts during COVID-19 lockdown

In a rigorous medRxiv* preprint paper, a group of researchers demonstrate shifts in age structure and clinical characteristics of individuals affected with coronavirus disease (COVID-19) after social and economic reopening in three US states and show how elderly individuals were less able to reduce contacts when compared to the younger ones.

19 Nov 2020

Seroprevalence meta-analysis predicts 643 million already infected by SARS-CoV-2 globally

A recent systematic review and meta-analysis conducted by a team of international scientists reveal low seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the general population.

19 Nov 2020

Pregnant women with COVID-19 have low risk of developing severe symptoms

Pregnant women who test positive for COVID-19 and their newborn babies have a low risk of developing severe symptoms, according to a new study from UT Southwestern.

19 Nov 2020

Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

In a recent study, a team of researchers at Northwestern University, USA, had found that nearly 20 percent seroprevalence in the United States metropolitan site, Chicago, over the summer, during a period when lockdown restrictions were eased. They found that three-quarters of seropositive individuals retained detectable antibodies for at least 120 days or four months.

19 Nov 2020